Author

P. Reimann

Observed name: P.G. Reimann

Institution: Landeskrankenhaus Feldkirch

Observed institutions: Landeskrankenhaus Feldkirch, 4SC (Germany), Private University in the Principality of Liechtenstein

ORCID: 0000-0002-6355-4591

Observed ORCID: 0000-0002-6355-4591

OpenAlex ID: A5048452374

NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data

2025 · A. Reichinger, A. Friedrich, et al. · ESMO Open · 8

A multicenter, d ouble blind, randomized, placebo-controlled, phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (stage IIB–IVB) mycosis fungoides (MF) or Sézary syndrome (SS) that have achieved disease control with systemic therapy: the RESMAIN study

2019 · R. Stadler, J. Scarisbrick, et al. · European Journal of Cancer · 3

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study

2026 · F. Moik, F. Huemer, et al. · ESMO Open · 2

530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study

2024 · A. Seeber, F. Huemer, et al. · Annals of Oncology · 1

2167P Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study

2023 · M.T. Mark, A. Rojas Mora, et al. · Annals of Oncology · 1

1153TiP A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study

2020 · A.C.J. van Akkooi, P.A. Ascierto, et al. · Annals of Oncology · 1

402P Early-onset pancreatic cancer: Clinical characteristics, treatment patterns, and outcomes in a real-world multicenter cohort from the Austrian advanced pancreatic cancer registry (ADPACA)

2026 · J.M. Riedl, A.M. Süß, et al. · Annals of Oncology

271P Real-world evidence analysis of NALIRIFOX in metastatic pancreatic ductal adenocarcinoma

2025 · A. Friedrich, A. Reichinger, et al. · Annals of Oncology

1520P Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis

2024 · A. Reichinger, H. Taghizadeh, et al. · Annals of Oncology

194P Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study

2023 · D. Barth, F. Moik, et al. · Annals of Oncology

Works count: 10

Citation count: 16

H-index: 2

I10-index: